• The company that makes OxyContin could become a ’public trust’ – what would that mean?
    http://theconversation.com/the-company-that-makes-oxycontin-could-become-a-public-trust-what-w

    Purdue Pharma, which makes OxyContin and other potentially addictive prescription opioids, has declared bankruptcy. It’s also facing thousands of lawsuits for its leading role in creating the opioid crisis.

    The company is trying to reach a broad settlement with the many jurisdictions now suing. The settlement it’s proposing would transform the company from a profit-seeking privately held company into a “public beneficiary trust” that serves the public good.

    I study the history of prescription drugs. Although there are some recent efforts to establish nonprofit drugmakers to help make certain pharmaceuticals more readily available, I know of no historical precedent for a big drugmaker like Purdue becoming a nonprofit public health provider.

    But two similarly ambitious efforts to build alternatives to the profit-driven pharmaceutical model during and immediately after World War II suggest the potential limits of how well this arrangement might work.

    By all accounts, the new trust would be a for-profit entity. Indeed, profits from continued sales of pain medicines like OxyContin and addiction treatment medications like buprenorphine and naloxone – estimated by Purdue to be up to US$8 billion per year – are crucial as the “payment” Purdue is offering to compensate the public for the company’s share of the costs of the opioid crisis.

    In other words, to achieve its mission, the new Purdue would have to pursue profits just like the old Purdue. And since all pharmaceutical companies officially declare themselves to be dedicated to serving the public good, how different would it really be?

    Then, too, the new trust would still be Purdue Pharma, a company with a well-entrenched culture of maximizing sales and profits even as the opioid crisis grew. One could make a credible case that Purdue’s innovations – the “value” it brought to the table – were not related to any special therapeutic breakthrough in the drugs it developed but instead lay in its genius with marketing these products.

    I can see why it is tempting to be excited about the prospect of a new public-benefit trust devoted to addressing addiction.

    But for this proposed arrangement to make sense, Purdue would need the tools and expertise required to pursue a radically different mission than it was designed to serve. And history does not offer much assurance that isolated public-sector and nonprofit drugmakers can make a big difference in a pharmaceutical system designed for and powered by profit.

    #Purdue_pharma #Sackler #Opioides

  • La pilule de l’obéissance

    À l’origine, le remède ne devait concerner que les #enfants « hyperactifs », une pathologie relativement rare. Mais depuis quelques années, aux États-Unis, tout bambin quelque peu turbulent peut se voir prescrire de la #Ritaline, un #médicament voisin des amphétamines qui fait également fureur sur les campus. Après avoir inondé le marché américain, la pilule miracle se répand en France.

    https://www.monde-diplomatique.fr/2019/12/BRYGO/61087
    #santé #enfance #hyperactivité

    • Déjà en cours il y a une dizaine d’années. Je ne connais pas l’ampleur du problème, mais j’avais rencontré une mère abandonnée — je trouve ça mieux que « mère célibataire » qui peut laisser penser que sa situation était un choix — épuisée qui n’arrivait pas à contrôler l’énergie de son petit dernier (essentiellement par manque d’aide et de ressources). Elle était soulagée par la mise sous Ritaline de son gosse. C’était effrayant de voir ce gosse domestiqué façon robot, mais je ne pouvais absolument rien dire à ce sujet à cette mère qui était déjà dans une grande souffrance.


    • #shit_storm en vue

      Le petit dernier, l’Adhansia, sort des usines de Purdue Pharma , le laboratoire de l’OxyContin, considéré comme le principal responsable de la crise des #opioïdes (400 000 morts en vingt ans) (11). « Je viens d’un programme où on essaie de baisser les doses, de favoriser les thérapies comportementales, d’arrêter les médicaments, poursuit Mme O’Rourke. Mon but, c’est qu’ils soient capables d’être des enfants, de jouer et d’apprendre. Je n’ai jamais vu d’effets négatifs à long terme, excepté une croissance perturbée. Le plus grand problème, ce serait l’addiction, surtout pour les adolescents, ainsi que la revente. » Pour elle, ça ne fait pas de doute, « la télévision est responsable en grande partie du TDAH. C’est la première baby-sitter du pays ». Dans sa salle d’attente, encore un garçon. Jayden, 12 ans, « ne tient pas en place ». Diagnostiqué hyperactif, il est sous psychotropes depuis quatre ans. Sa mère, Tasha, commente : « Quand il ne les prend pas, il est insupportable. » L’école ? « Je pense que c’est ennuyeux, répond Jayden. Lire est ennuyeux. Rester assis toute la journée est ennuyeux. Je préfère jouer au base-ball avec mon père, ou à Fortnite, World of Warcraft ou NBA 2K [des jeux vidéo] avec mes copains. »

    • On ne parle que des garçons par rapport à ces produits. C’est peut être une solution que les femmes (mères, personnel enseignant et personnel medical qui sont largment fémininisés) ont trouvé pour rendre un peu moins insupportables les comportements masculins.

      « Je préfère jouer au base-ball avec mon père, ou à Fortnite, World of Warcraft ou NBA 2K [des jeux vidéo] avec mes copains. »
      Il me semble qu’il y a une histoire de domination masculine dans tout ceci, les filles sont « rithalinés » sans chimie par la culture du viol.

    • Quand même @monolecte il y a aussi des femmes qui foutent le père dehors, souvent avec raison d’ailleurs ! et même si il est très content de retrouver sa « liberté » et qu’il ne paye pas la pension, j’estime que cela n’en fait pas une « femme abandonnée » pis on dirait qu’on parle d’un chien. Non plus qu’une femme célibataire, d’ailleurs. #famille_monoparentale c’est pas mal parce que oui, même seule avec un enfant c’est une famille, n’en déplaise à certaines pourritures de psys. Alors disons #mère_monoparentale ?

    • @mad_meg

      les filles sont « rithalinés » sans chimie par la culture du viol

      Affreusement d’accord avec toi :/

      https://onlinelibrary.wiley.com/doi/abs/10.1002/cbl.30337

      It is estimated that half to three‐quarters of all women with attention‐deficit/hyperactivity disorder (ADHD) are undiagnosed. Boys are more likely to be given an ADHD diagnosis (13.2%) than girls (5.6%). Girls are also diagnosed, on average, 5 years later than boys (boys at age 7, girls at age 12) (Foley, 2018).

  • Watch Richard Sackler Deny His Family’s Role in the Opioid Crisis — ProPublica
    https://www.propublica.org/article/watch-richard-sackler-deny-his-familys-role-in-the-opioid-crisis

    Des vidéos (répugnantes) de Richard Sackler répondant au procureur du Kentucky. Les yeux clairs des assassins tant décrit par les romans et les chansons.

    Four years ago this week, Dr. Richard Sackler sat in a conference room at a law office in a Louisville, Kentucky, office park. Lawyers for the Kentucky attorney general’s office were taking his deposition as part of the state’s lawsuit alleging that the family business, Purdue Pharma, illegally marketed the opioid painkiller OxyContin by understating its addictive properties.

    Sackler, who has been at various times Purdue’s president and co-chairman of its board, testified for more than eight hours. The lawyers asked him about his role at the company, what decisions he was involved in and whether he believes Purdue played any part in the opioid crisis that has resulted in more than 200,000 overdose deaths related to prescription drugs since 1999.

    Despite hundreds of lawsuits against Purdue stretching back well over a decade, that August 2015 deposition, which was recorded on video, is believed to be the first time any member of the Sackler family was questioned under oath about their role in the marketing of OxyContin.

    #Opioides #Richard_Sackler #Sackler #Vidéos

  • Inside Purdue Pharma’s Media Playbook : How It Planted the Opioid “Anti-Story” — ProPublica
    https://www.propublica.org/article/inside-purdue-pharma-media-playbook-how-it-planted-the-opioid-anti-story

    In 2004, Purdue Pharma was facing a threat to sales of its blockbuster opioid painkiller OxyContin, which were approaching $2 billion a year. With abuse of the drug on the rise, prosecutors were bringing criminal charges against some doctors for prescribing massive amounts of OxyContin.

    That October, an essay ran across the top of The New York Times’ health section under the headline “Doctors Behind Bars: Treating Pain is Now Risky Business.” Its author, Sally Satel, a psychiatrist, argued that law enforcement was overzealous, and that some patients needed large doses of opioids to relieve pain. She described an unnamed colleague who had run a pain service at a university medical center and had a patient who could only get out of bed by taking “staggering” levels of oxycodone, the active ingredient in OxyContin. She also cited a study published in a medical journal showing that OxyContin is rarely the only drug found in autopsies of oxycodone-related deaths.

    “When you scratch the surface of someone who is addicted to painkillers, you usually find a seasoned drug abuser with a previous habit involving pills, alcohol, heroin or cocaine,” Satel wrote. “Contrary to media portrayals, the typical OxyContin addict does not start out as a pain patient who fell unwittingly into a drug habit.”

    The Times identified Satel as “a resident scholar at the American Enterprise Institute and an unpaid advisory board member for the Substance Abuse and Mental Health Services Administration.” But readers weren’t told about her involvement, and the American Enterprise Institute’s, with Purdue.

    Among the connections revealed by emails and documents obtained by ProPublica: Purdue donated $50,000 annually to the institute, which is commonly known as AEI, from 2003 through this year, plus contributions for special events, for a total of more than $800,000. The unnamed doctor in Satel’s article was an employee of Purdue, according to an unpublished draft of the story. The study Satel cited was funded by Purdue and written by Purdue employees and consultants. And, a month before the piece was published, Satel sent a draft to Burt Rosen, Purdue’s Washington lobbyist and vice president of federal policy and legislative affairs, asking him if it “seems imbalanced.”

    Purdue’s tactics are reminiscent of the oil and gas industry, which has been accused of promoting misleading science that downplays its impact on climate change, and of big tobacco, which sought to undermine evidence that nicotine is addictive and secondhand smoke is dangerous.

    Media spinning was just one prong of Purdue’s strategy to fend off limits on opioid prescribing. It contested hundreds of lawsuits, winning dismissals or settling the cases with a provision that documents remain secret. The company paid leading doctors in the pain field to assure patients that OxyContin was safe. It also funded groups, like the American Pain Foundation, that described themselves as advocates for pain patients. Several of those groups minimized the risk of addiction and fought against efforts to curb opioid use for chronic pain patients.

    She has become an influential voice on opioids, addiction and pain treatment. Her writings have been published in The Wall Street Journal, USA Today, The Atlantic, Slate, Health Affairs, Forbes, Politico and elsewhere. She frequently appears on panels, television shows and in newspaper articles as an expert on the opioid crisis and pain prescribing guidelines. “We’ve entered a new era of opiophobia,” she recently told The Washington Post.

    Satel has been a resident scholar at the American Enterprise Institute since 2000. Among the notable figures who have spent time at AEI are the late Supreme Court Justice Antonin Scalia and former Trump national security adviser John Bolton. Current fellow Scott Gottlieb returned to AEI this year after serving as commissioner of the U.S. Food and Drug Administration, which approves and regulates prescription drugs like OxyContin.

    Purdue said its annual payments of $50,000 to AEI were part of the institute’s corporate program. That program offers corporations the opportunity to “gain access to the leading scholars in the most important policy areas for executive briefings and knowledge sharing,” according to the institute’s website.

    Purdue’s counterattack against an ambitious investigative series about OxyContin abuse may have contributed to that drop. An October 2003 series in the Orlando Sentinel, “OxyContin Under Fire,” found that Purdue’s aggressive marketing combined with weak regulation had contributed to “a wave of death and destruction.”

    The series, however, was marred by several errors that were detailed in a front-page correction nearly four months later. The reporter resigned, and two editors on the series were reassigned. While acknowledging the mistakes, the newspaper did not retract the series, and its review upheld the conclusion that oxycodone was involved in a large number of the overdoses in Florida.

    Dezenhall Resources, in an email, took credit for forcing the newspaper to issue the corrections. “Dezenhall’s efforts resulted in a complete front-page retraction of the erroneous 5-day, 19-part, front-page Orlando Sentinel series,” Hershow wrote in a 2006 email summarizing Dezenhall’s work for Purdue under the subject line “Success in Fighting Negative Coverage.”

    Purdue officials and the company’s public relations agencies came up with a 13-point plan to generate media coverage of the errors. It included getting a doctor to talk about how the series “frightened and mislead (sic) the people of Florida” and having a pain patient write a newspaper opinion column on the subject. The Sentinel series, one Purdue official wrote to other company executives and Dezenhall’s Hershow, was an opportunity to let the country know about “all of the sensational reporting on OxyContin abuse over the past 4 years. The conclusion: this is the most overblown health story in the last decade!”

    In the six years after Purdue challenged the Sentinel’s findings, the death rate from prescription drugs increased 84.2% in Florida. The biggest rise, 264.6%, came from deaths involving oxycodone. The state became a hotbed for inappropriate opioid prescribing as unscrupulous pain clinics attracted out of state drug seekers. The route traveled by many from small towns in Appalachia to the Florida clinics was nicknamed the “Oxycontin Express.”

    In 2017, 14 years after the Sentinel series was published, the Columbia Journalism Review described it as “right too soon” and said it “eerily prefigured today’s opioid epidemic.”

    Purdue also added Stu Loeser to its stable. The head of an eponymous media strategy company, Loeser was press secretary for Michael Bloomberg when he was mayor of New York City, and he is now a spokesman for Bloomberg’s possible presidential bid.

    Soon after Loeser began representing Purdue, Satel wrote in a 2018 piece for Politico headlined, “The Myth of What’s Driving the Opioid Crisis,” about “a false narrative” that the opioid epidemic “is driven by patients becoming addicted to doctor-prescribed opioids.”

    Loeser told Purdue executives in an email that “we are going to work with AEI to ‘promote’ this so it comes across as what it is: their thoughtful response to other writing.” His team was working to target the Satel story “to land in social media feeds of people who have searched for opioid issues and potentially even people who have read specific stories online,” he added.

    Loeser said in an interview that he didn’t end up working with AEI to promote the story. He said Purdue is no longer a client.

    Une belle bande d’ordures accoquinée avec une brochette de journaux peu regardants (quoique parmi les meilleurs du monde, ce qui est encore plus inquiétant).

    #Opioides #Sackler #Purdue_Pharma #Médias #Fake_news #Conflits_intérêt #Complicités #New_York_Times #Public_relation

  • Opioid prescription doses are increasingly being tapered, often more rapidly than recommended : Physicians advise caution, collaboration with patients on tapering plans — ScienceDaily
    https://www.sciencedaily.com/releases/2019/11/191118100836.htm

    Baisser trop vite les doses d’opioides a également des conséquences dramatiques... la crise est là pour durer. Il faut la prendre en compte, et faire participer les Sackler et les autres profiteurs et organisateurs de la vente des opioides aux coûts d’une désintoxication réussie.

    Stigma and safety fears have made daily dose tapering of opioid prescriptions more common. New research from UC Davis Health physicians, however, shows tapering can occur at rates as much as six times higher than recommended, putting patients at risk of withdrawal, uncontrolled pain or mental health crises.

    The study — “Trends and Rapidity of Dose Tapering Among Patients Prescribed Long-term Opioid Therapy, 2008-2017” — is published in JAMA Network Open. The results also will be presented at the Nov. 16-19 North American Primary Care Research Group meeting in Toronto.

    “Tapering plans should be based on the needs and histories of each patient and adjusted as needed to avoid adverse outcomes,” said study author Alicia Agnoli, assistant professor of family and community medicine. “Unfortunately, a lot of tapering occurs due to policy pressures and a rush to get doses below a specific and sometimes arbitrary threshold. That approach can be detrimental in the long run.”

    They also found that the rate of dose reduction often was well beyond the CDC’s recommendation of 10% per month. The average reduction overall was 27.6% per month. Nearly 20% of patients tapered at a rate of 40% per month, and 5% tapered at a rate faster than 60% per month.

    The 2016 policy could have been misinterpreted, leading many prescribers and health systems to insist on faster-than-recommended tapering, according to Agnoli.

    “There is definitely a lot of pressure to reduce opioid use among patients, but there also is a need for more training and guidance for prescribers on how to help them safely do so,” Agnoli said.

    #Opioides #Désintoxication

  • Amour, gloire et opioïdes – Binge Audio
    https://www.binge.audio/amour-gloire-et-opioides

    Des podcast sur la crise des opioides

    La crise des opioïdes est désormais mondiale : 34 million de personnes en consomment, 27 millions y sont accros, et les morts se comptent par centaines de milliers.

    Cette crise est particulièrement forte aux Etats-Unis, où une famille est considérée comme responsable de cette addiction généralisée : les Sackler, propriétaires des laboratoires Purdue Pharma qui commercialisent l’OxyContin, le médicament à l’origine du problème.

    Retour sur l’histoire de cette famille, milliardaire et mécène, devenue paria.

    #Sackler #Opioides

  • Addicted to Screens? That’s Really a You Problem - The New York Times
    https://www.nytimes.com/2019/10/06/technology/phone-screen-addiction-tech-nir-eyal.html

    Nir Eyal does not for a second regret writing Silicon Valley’s tech engagement how-to, “Hooked: How to Build Habit-Forming Products,” even as he now has a new book out on how to free ourselves of that same addiction.

    In his original manual for building enthralling smartphone apps, Mr. Eyal laid out the tricks “to subtly encourage customer behavior” and “bring users back again and again.” He toured tech companies speaking about the Hook Model, his four-step plan to grab and keep people with enticements like variable rewards, or pleasures that come at unpredictable intervals.

    “Slot machines provide a classic example of variable rewards,” Mr. Eyal wrote.

    Silicon Valley’s technorati hailed “Hooked.” Dave McClure, the founder of 500 Startups, a prolific incubator, called it “an essential crib sheet for any start-up looking to understand user psychology.”

    But that was 2014. That was when making a slot-machinelike app was a good and exciting thing. When “seductive interaction design” and “design for behavior change” were aspirational phrases.

    “Nir Eyal’s trying to flip,” said Richard Freed, a child psychologist who supports less screen time. “These people who’ve done this are all trying to come back selling the cure. But they’re the ones who’ve been selling the drugs in the first place.”

    “I’m sure the cigarette industry said there’s just a certain number of people with a propensity for lung disease,” he added.

    Mr. Eyal said he was not reversing himself. His Hook Model was useful, certainly, and he believed in the tactics. But it was not addicting people. It’s our fault, he said, not Instagram’s or Facebook’s or Apple’s.

    “It’s disrespectful for people who have the pathology of addiction to say, ‘Oh, we all have this disease,’” he said. “No, we don’t.”

    #Médias_sociaux #Addiction #Dopamine #Mir_Eyal

  • Purdue Pharma Warns That Sackler Family May Walk From Opioid Deal - The New York Times
    https://www.nytimes.com/2019/09/19/health/purdue-sackler-opioid-settlement.html

    Après avoir été maïtres-assdassins, les Sacklers deviennent Maîtres chanteurs. Belle famille.
    Pour tout savoir, un seul livre : « Addiction sur ordonnance » par Patrick Radden Keefe https://cfeditions.com/addiction

    Members of the Sackler family could withdraw their pledge to pay $3 billion as part of a nationwide deal to address the opioid crisis if a bankruptcy judge does not block outstanding state lawsuits against them and their company, Purdue Pharma, Purdue lawyers said in a legal complaint.

    Whether the threat is posturing or real, the move by Purdue, the maker of OxyContin, to inject it into the company’s bankruptcy proceeding could jeopardize the tentative settlement it reached last week with representatives of thousands of local governments that have brought lawsuits against it. Two dozen state attorneys general who have sued the company in their own courts have signed on to the agreement, too.

    The $3 billion to be paid over seven years, plus another contribution the Sacklers would make with the proceeds of the sale of their British drug company, Mundipharma, is a key component of the deal. But all lawsuits must be resolved, the lawyers said.

    The new complaint, filed in bankruptcy court in White Plains on Wednesday night, is aimed at about two dozen states that have not signed on to the settlement and are continuing to pursue cases against both the company and various Sacklers.

    #Sackler #Too_much #Opioides

  • En ciblant Purdue Pharma, « l’appareil judiciaire américain s’attaque au capitalisme débridé »
    https://www.lemonde.fr/economie/article/2019/09/16/en-ciblant-purdue-pharma-l-appareil-judiciaire-americain-s-attaque-au-capita

    Aujourd’hui, face à une crise qui à elle seule a réussi à faire chuter l’espérance de vie aux Etats-Unis, la quasi-totalité des Etats du pays a lancé des poursuites pour réclamer des dédommagements au nom du million de familles touchées par ce fléau. Au total, 2 600 plaintes ont été enregistrées. Pour tenter d’éteindre l’incendie, la société a demandé, dimanche 15 septembre, à être placée sous la protection du chapitre 11 de la loi sur les faillites. Et elle propose une résolution globale spectaculaire : la nationalisation de Purdue.
    Nationalisation des pertes

    Il s’agirait de confier la gestion de l’entreprise et l’ensemble de ses gains futurs à un trust représentant les Etats, l’ensemble des bénéfices leur étant reversés pour financer l’aide aux victimes et la recherche sur la lutte contre l’addiction. La transaction est évaluée à dix milliards de dollars et la famille Sackler a promis d’y ajouter trois milliards. Vingt-neuf Etats et territoires ont accepté la transaction, mais 26 autres s’y opposent formellement, dont celui de New York.

    Ils ne sont pas du tout d’accord avec cette nouvelle version de la privatisation des gains et de la nationalisation des pertes. Car, durant toutes ces années, la famille Sackler a vu sa fortune exploser, pour représenter, selon Forbes, près de 13 milliards de dollars. Elle doit rendre gorge, exigent les procureurs généraux, sortes de ministre de la justice des Etats. D’autant que l’enquête de celui de New York affirme que près d’un milliard de dollars aurait été discrètement envoyé en Suisse pour échapper au fisc.

    #Purdue_Pharma #Opioides #Capitalisme_sauvage #Sackler

  • Purdue Pharma annonce se déclarer en faillite pour régler la crise des opiacés AFP - 16 Septembre 2019 - RTBF

    Le groupe pharmaceutique américain Purdue Pharma a annoncé dimanche qu’il allait se déclarer en faillite dans le cadre d’un accord à l’amiable, espérant en tirer 10 milliards de dollars pour solder des milliers de plaintes liées à la crise des opiacés.

    Le président de Purdue, Steve Miller, a précisé dans un communiqué que cet accord « fournira des milliards de dollars et des ressources essentielles aux collectivités de tout le pays qui tentent de faire face à la crise des opiacés ».

    En vertu de cet accord, toutefois assujetti à l’approbation d’un tribunal, la totalité de la valeur du groupe Purdue sera versée à un organisme établi au bénéfice des plaignants et de la population américaine.

    Purdue Pharma, fabricant d’un des principaux médicaments anti-douleur aux opiacés, l’OxyContin, fait l’objet de plus de 2.000 plaintes.

    Le groupe a déclaré s’être placé sous la protection de la loi américaine sur les faillites - « Chapitre 11 » - et a précisé que le conseil d’administration d’une nouvelle entreprise serait choisi par les plaignants avant d’être approuvé par le tribunal des faillites.

    M. Miller a également indiqué que cette restructuration éviterait de « gaspiller des centaines de millions de dollars et des années en litiges prolongés ».

    Dans le cadre de l’accord, l’entreprise pourrait fournir des millions de médicaments nécessaires au traitement de la toxicomanie, tels que le Nalmefene et le Naloxone, gratuitement ou à coût faible.

    En plus de l’abandon du contrôle de Purdue, la riche famille américaine Sackler pourrait à titre privé devoir notamment contribuer à hauteur de 3 milliards de dollars.

    Très influents au sein du gotha new-yorkais, les Sackler ont bâti leur fortune sur l’OxyContin, ce puissant antidouleur accusé d’être au coeur de la crise des opiacés à l’origine de 47.000 morts par overdose aux Etats-Unis en 2017.

    Source : https://www.rtbf.be/info/economie/detail_purdue-pharma-annonce-se-declarer-en-faillite-pour-regler-la-crise-des-o

    #Opioides #Sackler #Philanthropie #Procès #Accord_amiable #Procès #mécénat #Oxycontin #big_pharma #drogues #opiacés #addiction #drogue #pharma #santé_publique #overdose #philantropophagie

  • Tentative opioids settlement falls short of nationwide deal
    https://www.apnews.com/fcb693fee634449cb8a0dc146251b18d

    HARTFORD, Conn. (AP) — A tentative settlement announced Wednesday over the role Purdue Pharma played in the nation’s opioid addiction crisis falls short of the far-reaching national settlement the OxyContin maker had been seeking for months, with litigation sure to continue against the company and the family that owns it.

    The agreement with about half the states and attorneys representing roughly 2,000 local governments would have Purdue file for a structured bankruptcy and pay as much as $12 billion over time, with about $3 billion coming from the Sackler family. That number involves future profits and the value of drugs currently in development.

    In addition, the family would have to give up its ownership of the company and contribute another $1.5 billion by selling another of its pharmaceutical companies, Mundipharma.

    Several attorneys general said the agreement was a better way to ensure compensation from Purdue and the Sacklers than taking their chances if Purdue files for bankruptcy on its own.

    Arizona Attorney General Mark Brnovich said the deal “was the quickest and surest way to get immediate relief for Arizona and for the communities that have been harmed by the opioid crisis and the actions of the Sackler family.”

    In a statement after Wednesday’s announcement, the company said that it “continues to work with all plaintiffs on reaching a comprehensive resolution to its opioid litigation that will deliver billions of dollars and vital opioid overdose rescue medicines to communities across the country impacted by the opioid crisis.”

    Even with Wednesday’s development, many states have not signed on. Several state attorneys general vowed to continue their legal battles against the Sacklers and the company in bankruptcy court. Roughly 20 states have sued members of the Sackler family in state courts.

    Connecticut, Iowa, Massachusetts, Nevada, New Jersey, New York, Pennsylvania, North Carolina and Wisconsin were among the states saying they were not part of the agreement.

    “Our position remains firm and unchanged and nothing for us has changed today,” Connecticut Attorney General William Tong said in a statement.

    “The amount of money that’s being offered in this settlement doesn’t even scratch the surface for what’s needed,” Hampton said. “We want to see Purdue have their day in court. We know more money will come if this case goes to trial.”

    Les ordures sans vergogne :

    On Wednesday, the Sackler family said in a statement that it “supports working toward a global resolution that directs resources to the patients, families and communities across the country who are suffering and need assistance.”

    “This is the most effective way to address the urgency of the current public health crisis, and to fund real solutions, not endless litigation,” it said.

    In March, Purdue and members of the Sackler family reached a $270 million settlement with Oklahoma to avoid a trial on the toll of opioids there.

    A court filing made public in Massachusetts this year asserts that members of the Sackler family were paid more than $4 billion by Purdue from 2007 to 2018. Much of the family’s fortune is believed to be held outside the U.S., which could complicate lawsuits against the family over opioids.

    The Sacklers have given money to cultural institutions around the world, including the Smithsonian Institution, New York City’s Metropolitan Museum of Art and London’s Tate Modern.

    #Opioides #Sackler #Procès #Accord_amiable

  • Sacklers Reject Demand That They Surrender Personal Wealth To Settle Opioid Claims : NPR
    https://www.npr.org/2019/09/09/758927743/sacklers-reject-demand-they-surrender-personal-wealth-to-settle-opioid-claims

    The family that owns Purdue Pharma, maker of Oxycontin, has rejected a demand that they give up $4.5 billion of their personal wealth to settle opioid claims against the company, according to state attorneys general negotiating with the company.

    As a consequence, talks toward a national settlement with members of the Sackler family reached an impasse over the weekend, according to an email obtained by NPR.

    Two attorneys general directly involved in the talks predicted in the email that the company will now file for bankruptcy “imminently.”

    “States have already begun preparations for handling the bankruptcy proceedings,” wrote Josh Stein, North Carolina’s state attorney general, and Herbert Slatery, attorney general for Tennessee.

    “The Sacklers refused to budge,” the email concluded, “and have declined to offer any counterproposal.”

    The email, first reported by The Associated Press, was sent Saturday to other state attorneys general. It details an offer made to the Sacklers that would have forced them to pay billions of dollars to compensate states for their role helping to fuel the prescription opioid epidemic.

    The deal would also have forced Purdue Pharma into bankruptcy proceedings while dissolving the Sacklers’ overseas opioid business.

    But in a statement emailed to NPR Sunday night, the drug company suggested a deal might still be possible.

    “Purdue Pharma believes a settlement that benefits the American public now is a far better path than years of wasteful litigation and appeals,” the statement said. “Those negotiations continue and we remain dedicated to a resolution that genuinely advances the public interest.”

    Overdose deaths linked to prescription opioids have killed more than 218,000 Americans since the addiction crisis began in the late 1990s, according to the Centers for Disease Control and Prevention.

    State and local governments have filed more than 2,000 lawsuits claiming Purdue Pharma played a central role marketing opioid medications, while downplaying the risks.

    Over two decades, opioid sales generated billions of dollars in profits for the company, making the Sacklers one of the richest families in the U.S.

    A spokesperson for Purdue Pharma declined an interview request by NPR and wouldn’t say whether the company is, in fact, considering an immediate bankruptcy filing. Last March, company officials acknowledged that filing for Chapter 11 protection is one strategy being considered.

    If Purdue Pharma does file for bankruptcy without first reaching some kind of structured deal, it could take years to sort out the remaining value of the company’s assets and then determine who’s first in line for compensation.

    Pressure to reach a settlement is also intensifying because a federal opioid trial involving Purdue Pharma and more than 20 other drugmakers, distributors and pharmacy chains is set to begin next month in Cleveland.

    While that legal process moves forward, state attorneys general have promised to continue pursuing the Sacklers personally to recoup profits the family received from opioid sales, even if Purdue Pharma seeks Chapter 11 protection.

    “I won’t let them get away with their crimes,” Pennsylvania Attorney General Josh Shapiro wrote Saturday on Twitter. “I will sue them personally, so that we can dig into their personal pocketbooks.”

    The Wall Street Journal also reported Friday that the U.S. Justice Department is involved in separate talks with Purdue Pharma.

    According to the newspaper, those negotiations involve possible civil penalties tied to federal probes of Oxycontin sales, but could also include criminal charges using statutes normally used to prosecute drug dealers.

    #Opioides #Sackler #Procès

  • Opinion | These Newborn Babies Cry for Drugs, Not Milk - The New York Times
    https://www.nytimes.com/2019/09/07/opinion/sunday/babies-opioid-addiction-west-virginia.html

    Un éditorial plein de fougue et de colère, très bien écrit et qui pose les véritables questions de la rapacité, des entreprises et de la défaillance du système pour réguler celles-ci.

    His body dependent on opioids, he writhes, trembles and cries. He is exhausted but cannot sleep. He vomits, barely eats and has lost weight.

    He is also a baby. Just 1 month old, he wails in the nursery of the CAMC Women and Children’s Hospital here. A volunteer “cuddler” holds him while walking around, murmuring sweetly, hour after hour, but he is inconsolable. What his body craves is heroin.

    Every 15 minutes in America, a child is born after a prenatal exposure to opioids. Here in West Virginia, 14 percent of babies are born exposed to drugs, and perhaps 5 percent more to alcohol, totaling nearly one out of five newborns. Some get by without symptoms, but for many, their very first experience after birth is the torment of withdrawal.

    Pharmaceutical executives are battling lawsuits by blaming drug users. I wish those executives had to cuddle these infants who, partly because of their reckless greed, suffer so much.

    Executives in three-piece suits were drug lords as guilty as any from Medellín. The Washington Post reported that pharma companies shipped 76 billion opioid pain pills from 2006 through 2012. A single pharmacy in Kermit, W.V., sold more than 13 million over those seven years — and Kermit has a population of just over 400 people.

    So today, hospitals in West Virginia and across America struggle to calm babies who sometimes begin to go through withdrawal as soon as the umbilical cord is cut.

    There’s plenty of blame to go around, encompassing opioid-abusing moms and opioid-prescribing doctors. But it’s appropriate to feel special loathing for executives at pharma companies whose corporate strategy was to profit by getting people hooked. Some of the companies funded a movement claiming that pain was the “fifth vital sign” and urged doctors to prescribe more painkillers, and then paid them kickbacks to do so.

    Almost 80 percent of heroin users began with prescription pain pills, though not necessarily prescribed to them.

    Newborn babies struggling through withdrawal are only one dimension of America’s opioid crisis. Every seven minutes another American dies of an overdose; 2.1 million children live with a parent with a drug dependency.

    McKinsey and Company, the global consulting company, issued a sober report last fall warning that “the opioid crisis will worsen over the next three to five years.” What McKinsey didn’t say was that it had previously advised Johnson & Johnson to be more aggressive in peddling opioids for back pain and to encourage doctors to prescribe stronger, more addictive pills.

    These drug-addicted newborns are suffering partly because of Johnson & Johnson, McKinsey, Purdue Pharma, McKesson and many other companies; these babies are a reminder of why corporate regulation is essential.

    #Opioides #Bébés

  • Opioid crisis goes global as deaths surge in Australia
    https://www.apnews.com/cfc86f47e03843849a89ab3fce44c73c

    Half a world away, Australia has failed to heed the lessons of the United States, and is now facing skyrocketing rates of opioid prescriptions and related deaths. Drug companies facing scrutiny for their aggressive marketing of opioids in America have turned their focus abroad, working around marketing regulations to push the painkillers in other countries. And as with the U.S., Australia’s government has also been slow to respond to years of warnings from worried health experts.

    In dozens of interviews, doctors, researchers and Australians whose lives have been upended by opioids described a plight that now stretches from coast to coast. Australia’s death rate from opioids has more than doubled in just over a decade. And health experts worry that without urgent action, Australia is on track for an even steeper spike in deaths like those seen in America, where the epidemic has left 400,000 dead.

    “If only Australia could understand how quickly this can get out of hand. We’re not immune to it,” says Jasmin Raggam, whose brother Jon died in 2014 of an opioid overdose and whose brother-in-law is now addicted to the opioid OxyContin. “I was screaming from the mountaintops after Jon died and I’d started doing my research. And it was like I’m screaming and nobody wants to hear me.”

    Opioids were once reserved for treating pain that was short-term, terminal or related to cancer. But in the 1990s, pharmaceutical companies began aggressively marketing them for chronic pain.

    Starting in 2000, Australia began approving and subsidizing certain opioids for use in chronic, non-cancer pain. Those approvals coincided with a spike in opioid consumption, which nearly quadrupled between 1990 and 2014, says Sydney University researcher Emily Karanges.

    A few years ago, a pharmacist at the hospital told her they needed to hire an extra person just to handle all the prescriptions they were handing out for Endone, a brand of oxycodone. Stevens discovered that the hospital’s Endone prescriptions had increased 500 percent in 8 years, with no decrease in other opioids dispensed. Further study revealed that 10 percent of patients were still taking opioids three months after surgery, even though the drugs are generally only recommended for short-term use.

    “We were just pumping this stuff out into our local community, thinking that that had no consequences,” says Stevens, a vocal advocate for changing opioid prescribing practices. “And now, of course, we realize that it does have huge consequences.”

    Just like in the U.S., as opioid prescriptions rose, so did fatal overdoses. Opioid-related deaths jumped from 439 in 2006 to 1,119 in 2016 — a rise of 2.2 to 4.7 deaths per 100,000 people, according to the Australian Institute of Health and Welfare. Most of those deaths were related to prescription opioids, rather than illegal opioids such as heroin.

    More than 3 million Australians - an eighth of the country’s population - are getting at least one opioid prescription a year, according to the latest data.

    In Australia, pharmaceutical companies by law cannot directly advertise to consumers, but are free to market the drugs to medical professionals. And they have done so, aggressively and effectively, by sponsoring swanky conferences, running doctors’ training seminars, funding research papers, giving money to pain advocacy groups and meeting with doctors to push the drugs for chronic pain.

    “If the relevant governing bodies had ensured that the way the product was being marketed to doctors especially was different, I don’t necessarily think we would see what we’re seeing now,” says Bee Mohamed, who until recently was the CEO of ScriptWise, a group devoted to reducing prescription drug deaths in Australia. “We’re trying to undo ten years of what marketing has unfortunately done.”

    Mundipharma, the international arm of Purdue, has received particular criticism for its marketing tactics in Australia. In 2018, addiction specialist Dr. Simon Holliday filed a complaint against the company over a marketing pamphlet for its drug Targin, a painkiller designed to prevent the constipation that is common with other opioids.

    The campaign, which encouraged people suffering painkiller-induced constipation to talk to their doctors, never mentions Targin by name, because it legally can’t. But the advertising agency Mundipharma hired described on its website how they worked around that regulation, by using print, radio and online ads to target regions where pain medication use was high. Google search data showed that people looking for information on constipation from painkillers used terms like “blocked up,” so the agency used the phrase “blocked pipes.”

    In a statement, Mundipharma said the campaign was a “disease awareness initiative” that did not violate the spirit of any law and did not market any medication.

    Stevens, the Sydney pain specialist, has pushed back against several drug companies over their marketing tactics. A couple years ago, she says, Mundipharma was marketing Targin to surgeons at her hospital, reassuring them that they could prescribe higher doses. Unlike pain specialists, surgeons are generally not well-educated on the intricacies of opioids, she says.

    In a statement, Mundipharma said it strictly adheres to the Medicines Australia code of conduct and has always been transparent about the risks associated with opioids. Still, in a submission last year to the TGA as it considered tougher restrictions on opioids, Mundipharma appeared to minimize the severity of Australia’s problem.

    “We acknowledge that there is an issue associated with opioid misuse,” the company wrote. “However to describe the Australian situation as a ‘crisis’ is alarmist and risks stigmatizing patients who have a legitimate need for opioid analgesics to manage their pain.”

    This is Australia’s poorest state, and like Appalachia, it is the country’s epicenter for opioids. Tasmania has the nation’s highest rate of opioid packs sold per person — 2.7 each. One region has the highest number of government-subsidized opioid prescriptions in Australia: more than 110,000 for every 100,000 people.

    Ten years ago, while working as a dairy farmer, Casey jumped off a truck and felt her knees give way. An operation provided temporary relief, but the pain came back. She was told she had osteoarthritis.

    A doctor prescribed her opioids to ease her pain. When she stuck the first patch on her skin, it felt like heaven.

    But the agony eventually returned, so the doctor upped the dosage. The side effects were hell — depression, anxiety, panic attacks. And her pain got worse.

    #Opioides #Australie #Mundipharma

  • Addiction treatment costs: She spent more than $110,000 on drug rehab. Her son still died. - Vox
    https://www.vox.com/policy-and-politics/2019/9/3/20750587/rehab-drug-addiction-treatment-sean-blake-opioid-epidemic

    In story after story, the same experience was repeated over and over: of patients and families getting sucked into an American rehab industry that is largely unregulated, shockingly ineffective, and ruinously expensive.

    Vox is launching an investigation into the notoriously opaque addiction rehab industry, called The Rehab Racket. We’re crowdsourcing the experiences of patients and families, with an emphasis on cost and quality of care. If you have a story you’d like to share with us, please visit our submissions page.

    Vox has launched The Rehab Racket, an investigation into America’s notoriously opaque addiction treatment industry. As part of this, we’re crowdsourcing patients and families’ rehab stories, with an emphasis on the cost of treatment and quality of care. If you’d like help our reporting by sharing your story, please fill out this survey.

    Addiction treatment is difficult work, but it can succeed, and evidence-based care does exist. For opioid addiction in particular, studies show medications like methadone and buprenorphine cut the death rate among patients by half or more.

    But the parents I spoke to have learned — as thousands of Americans discover each year — that much of the US rehab industry does not provide evidence-based, effective care.

    American rehab is dominated by a 12-step approach, modeled after Alcoholics Anonymous, that only works for some patients and doesn’t have strong evidence of effectiveness outside of alcohol addiction treatment.

    That’s often coupled with approaches that have even less evidence behind them. There’s wilderness therapy, focused largely on outdoor activities. There’s equine therapy, in which people are supposed to connect with horses. There’s a confrontational approach, which is built around punishments and “tough love.” The research for all these is weak at best, and with the confrontational approach, the evidence suggests it can even make things worse.

    “It is a scam,” Carol Beyer, founder of Families for Sensible Drug Policy and a mom in New Jersey, told me. She estimates she spent well over $100,000 on treatment — including 12-step and “tough love” programs — and still lost her two sons to drug overdoses.

    #Opioides #Rehabilitation #Capitalisme_sauvage

  • #Overdoses aux #opioïdes : l’#antidote existe mais reste trop difficile à se procurer
    https://www.francetvinfo.fr/sante/medicament/overdoses-aux-opioides-l-antidote-existe-mais-n-est-pas-encore-assez-di

    L’antidote à base de #naloxone pour stopper en urgence une surdose d’opioïdes médicamenteux ou illicites comme l’héroïne est encore très loin d’être facilement accessible à tous, ont dénoncé samedi 31 août l’association France patients experts addictions et plusieurs spécialistes.

    Des kits d’antidotes prêts à l’emploi pour stopper l’overdose en attendant l’arrivée des secours sont actuellement commercialisés en France : une forme injectable en intramusculaire, le Prenoxad, depuis mai 2019, et un spray nasal, le Nalscue, depuis 2018. "La procédure pour commander le Prenoxad est trop compliquée, les pharmaciens doivent s’adresser directement au laboratoire. En pratique, il n’est pas vraiment à la disposition de tous", explique le Pr Michel Reynaud, président du Fonds actions addictions.

    Une pharmacie sur quarante

    « D’après un testing réalisé avec une association d’usagers de drogues, l’antidote n’était présent que dans une pharmacie sur quarante et les deux tiers des pharmacies ne connaissaient pas ce produit », relève Michel Reynaud.

    La situation en France est certes sans commune mesure avec la crise des opioïdes aux Etats-Unis et leurs plus de 70 000 décès en 2017, selon le ministère de la Santé. Mais la tendance à l’augmentation des overdoses ces dernières années est préoccupante, en particulier celles dues à des médicaments antidouleurs, selon le Pr Nicolas Authier, de l’Observatoire français des médicaments antalgiques (Ofma)."Entre 2000 et 2015, les décès par overdoses d’opioïdes médicaments (hors héroïne et méthadone) sont passés de 75 à 200", dit-il et « c’est probablement une sous-estimation ».

  • #Big_Pharma paying a small price for opioid crisis - HoustonChronicle.com
    https://www.houstonchronicle.com/business/columnists/tomlinson/article/Big-Pharma-paying-a-small-price-for-opioid-crisis-14396082.php

    Et en plus ça s’indigne,

    The $572 million fine represents 2 percent of Johnson and Johnson’s annual profits. The company says it will appeal what it calls an unjust verdict.

    #fumisterie #dérisoire #opiacés #opioides

  • A Nun, a Doctor and a Lawyer — and Deep Regret Over the Nation’s Handling of Opioids - The New York Times
    https://www.nytimes.com/2019/08/18/health/opioids-purdue-pennington-gap.html

    PENNINGTON GAP, Va. — Years before there was an opioid epidemic in America, Sister Beth Davies knew it was coming.

    In the late 1990s, patient after patient addicted to a new prescription painkiller called OxyContin began walking into the substance abuse clinic she ran in this worn Appalachian town. A local physician, Dr. Art Van Zee, sensed the gathering storm, too, as teenagers overdosed on the drug. His wife, Sue Ella Kobak, a lawyer, saw the danger signs in a growing wave of robberies and other crimes that all had links to OxyContin.

    The Catholic nun, the doctor and the lawyer were among the first in the country to sound an alarm about the misuse of prescription opioids, the beginnings of a cycle of addiction that would kill 400,000 people in the ensuing two decades as it spread to illegal opioids like heroin and counterfeit versions of fentanyl. They led a burst of local activism against Purdue Pharma, OxyContin’s maker, that the company ultimately crushed. It would eventually help kindle national awareness that led to a wave of legal actions that are still awaiting resolution.

    The three also believe that the Justice Department could have changed the behavior of other opioid makers if it had charged executives of Purdue Pharma in 2007 with felonies, as federal prosecutors had recommended, in connection with OxyContin’s illegal marketing.

    Instead, department officials negotiated a deal under which the executives pleaded guilty to misdemeanor charges that did not include jail time. In the years that followed, executives of other opioid makers and distributors kept shipping millions of addictive pain pills into towns like this one apparently without fear of serious penalties.

    “I think the trajectory would have been completely different,” Dr. Van Zee said recently. “It would not have reached the magnitude that it did.”

    A local pharmacist, Greg Stewart, said a sales representative for Purdue Pharma had told him that OxyContin was safe because it was a long-acting narcotic and so would not appeal to drug abusers who liked Percocet and other short-acting pain pills because they delivered a quick high. But teenagers and others in town quickly discovered that crushing an OxyContin pill released large quantities of the narcotic oxycodone.

    Sister Beth recalls getting a phone call from Mr. Stewart as she was starting to see people addicted to the drug.

    “Beth, believe me,” she recalled him saying, “this is going to be the worst disaster that ever hit Lee County.”

    Sister Beth, Dr. Van Zee and Ms. Kobak, who is now retired, have been reading with fascination the new documents about Purdue Pharma and its owners, members of the wealthy Sackler family, that have recently emerged in lawsuits and elsewhere. As it turns out, it was in 2001, the year they and others in town confronted Purdue Pharma executives about the overzealous marketing of OxyContin, that a son of one of company’s founders, Dr. Richard Sackler, wrote a now infamous email about the need “to hammer on the abusers in every way possible” for the drug’s problem.

    “You lie so much you believe your own lies,” Sister Beth said. “That’s what devastates me; it was always profits over people.”

    Both Purdue Pharma and a representative for Dr. Sackler insist that the email and others cited in recent lawsuits have been taken out of context.

    The lawyers assured him, he said, that they wanted exactly what he did: to finally see all of Purdue Pharma’s internal documents brought to public light.

    “I was impressed by what looked like their commitment to get some type of accountability and responsibility,” he said.

    But that never happened. In March, Purdue Pharma agreed to pay $270 million to settle. As a result, all its internal documents remain sealed. Oklahoma state officials said they struck the deal because of concerns that Purdue Pharma, which faces thousands of lawsuits, might soon file for bankruptcy.

    #Opioides #Purdue_Pharma

  • Le « naming », un piège à Louvre Texte Nicolas Cori Photo Denis Allard/Réa Édité par François Meurisse - 6 Aout 2019 - Les Jours

    Le musée s’est embourbé dans un contrat de mécénat avec la généreuse famille Sackler, accusée d’avoir créé la crise des opioïdes aux États-Unis.

    Prenez La Joconde, son sourire mystérieux et ses millions de visiteurs annuels. Imaginez maintenant des hordes d’activistes dénoncer régulièrement devant elle la complicité du Louvre face à l’une des plus grandes crises sanitaires qu’ait connues les États-Unis.
    Un tel scénario a dû donner des cauchemars à la direction du musée parisien. Le 1er juillet dernier, une poignée de militants emmenés par la photographe américaine Nan Goldin, les pieds dans l’eau et des banderoles à la main, ont manifesté devant la pyramide du Louvre afin de demander à ce que l’aile Sackler des antiquités orientales soit débaptisée. La famille Sackler est propriétaire du groupe pharmaceutique Purdue Pharma, accusé d’avoir incité les médecins américains à prescrire à tout va depuis le début des années 2000 de l’Oxycontin, un analgésique contenant de l’opium, créant ainsi la plus grosse épidémie d’overdoses médicamenteuses jamais vue outre-Atlantique. Eh bien, quelques semaines après ce modeste happening, la direction du Louvre a décidé d’effacer en toute discrétion le nom de Sackler de ses salles, tout en adoptant une communication très alambiquée.

    Interrogé le 16 juillet sur RTL, Jean-Luc Martinez, le président du Louvre, a ainsi affirmé qu’il n’avait pas à « débaptiser ces salles » car elles ne portaient « plus le nom de Sackler » depuis des années, étant donné que le « nommage » des salles – datant des années 1990 – ne durait que « vingt ans ». Une information que, visiblement, seul l’intéressé possédait : pourquoi une manifestation quinze jours auparavant sinon ? Cet épisode est révélateur de la gêne de la direction du Louvre, mais aussi des problèmes éthiques pesant sur l’une des contreparties (lire l’épisode 2, « Les riches jouent aux gros dons ») les plus contestables du mécénat : le « naming » ou « nommage » d’espaces pour remercier un donateur particulièrement généreux. Permettre qu’une entreprise ou une personne fortunée donne son nom à un bout de musée, c’est prendre le risque de voir la réputation de l’établissement mise à mal si le mécène ne s’avère pas sans reproches. Et qui est sans tache ? Le récit du mécénat Sackler au Louvre permet de s’en rendre compte..

    Overdoses
    En 2015, le nombre d’overdoses mortelles dues à des médicaments opioïdes a atteint le chiffre de 33 000 contre 4 000 en 1994, avant l’introduction de l’Oxycontin. Ce médicament était à l’origine destiné à soulager les malades du cancer mais la firme Purdue Pharma a développé une politique marketing très agressive, convaincant les médecins de prescrire ce médicament à tous les publics. . . . . . . .

    La suite, payante sur : https://lesjours.fr/obsessions/mecenes-mecenat/ep5-louvre-sackler

    #art #musée #mécénat #culture #peinture #musées #exposition #mémoire #merci #france #opioides #sackler #Oxycontin #big_pharma #drogues #opiacés #addiction #drogue #pharma #santé_publique #overdose #opioids #Louvre #naming

    • Le discours de Nan Goldin
      « Je suis ici aujourd’hui pour demander à ce que le Louvre retire le nom “Sackler”. Il y a douze salles dans le département des antiquités orientales qui ont le nom “Sackler”. Les Sackler possèdent un groupe pharmaceutique qui a déchaîné la plus grande crise de santé publique aux États-Unis. Les gens meurent à cause d’eux. (…) 1,7 million de personnes sont dépendantes. »

  • Addiction sur ordonnance : la crise des antidouleurs, par Patrick Radden Keeke est disponible en version epub.
    https://cfeditions.com/addiction

    Bonjour,

    Il y a des coïncidences qui ne trompent pas.

    Hier soir j’ai mis en place la vente de la version epub de « Addiction sur ordonnance : la crise des antidouleurs ».

    Et ce matin on apprend via le New York Times que Le Louvre a décidé de retirer le nom des Sackler, la famille à l’origine de cette crise, de l’aile du musée financée par leur « philanthropie ».

    C’est le bon moment pour mieux comprendre les tenants et aboutissants de cette affaire. Les opioïdes tuent plus de 50000 personnes aux États-Unis chaque année, plongent les familles dans l’angoisse et le déchirement. Cette crise à commencé parce que des médecins ont prescrit sans retenue OxyContin, un antidouleur opiacé soi-disant "non-addictif" produit par Purdue Pharma, l’entreprise des Sackler. Une entreprise plus spécialiste du marketing que de la pharmacie.

    Or cette famille apparait aux yeux des mondes de l’art comme composée de grands « philanthropes », en effectuant des donations aux musées et aux universités. Grâce à la photographe Nan Goldin, de multiples actions ont lieu dans ces institutions, dont celle au Louvre le 1 juillet qui ne doit pas être pour rien dans la décision du musée de retirer la mention des Sackler.

    L’enquête qui a rendu public le lien entre la pratique de la famille Sackler et la crise des opioïdes a été écrite par Patrick Radden Keefe et publiée dans le New Yorker... et c’est elle que nous avons traduit et publié dans « Addiction sur ordonnance »

    Cette enquête se lit comme un roman noir... très noir.

    Vous pouvez l’emporter cet été dans votre liseuse, ou commander la version imprimée :
    https://cfeditions.com/addiction

    (et en principe dans la journée la version epub sera également disponible dans les diverses libraires numériques)

    Bonne lecture,

    Hervé Le Crosnier

    Addiction sur ordonnance : la crise des antidouleur
    Patrick Radden Keefe
    trad. de l’anglais par Claire Richard
    avec des compléments rédigés par Frédéric Autran, Cécile Brajeul et Hervé Le Crosnier
    Version imprimée - 16 € - ISBN 978-2-915825-90-9
    Version epub - 8 € - ISBN 978-2-915825-91-6
    commande, information et obtention d’un extrait spécimen :
    https://cfeditions.com/addiction

    #Sackler #Opioides #C&F_éditions

  • Louvre Removes Sackler Family Name From Its Walls - The New York Times
    https://www.nytimes.com/2019/07/17/arts/design/sackler-family-louvre.html

    The Louvre in Paris has removed the name of the Sackler family from its walls, becoming the first major museum to erase its public association with the philanthropist family linked with the opioid crisis in the United States.

    The Louvre’s collection of Persian and Levantine artifacts is housed in a wing that has been known as the Sackler Wing of Oriental Antiquities since 1997.

    But on Wednesday, a plaque acknowledging the Sacklers’ donations had been removed from the gallery’s entrance, and references to “the Sackler Wing” on other signs in the museum had been covered with gray tape.

    Members of the Sackler family own Purdue Pharma, the maker of OxyContin, an enormously profitable and frequently abused painkiller that is the subject of numerous lawsuits in the United States.

    Les faux-culs !!!

    Nine other signs in the building that referenced the wing had been taped over. Ms. Aguirre said another large sign that acknowledged the Sackler donation had also been removed.References to “the Sackler Wing” have also been removed from the Louvre’s website.

    On Tuesday, Jean-Luc Martinez, the museum’s president, told RTL, a French radio station, that the Sackler name had been taken down because the Louvre’s policy on naming rights is that they last for 20 years.

    A spokeswoman for the Louvre did not respond to emails asking why, if naming rights only lasted 20 years, the name had not been painted over earlier.

    The Sackler family declined to comment through a spokesman from Edelman, the public relations firm that represents them in Britain.

    Ms. Goldin said she recognized that many museums could not follow the Louvre’s example without breaking their contracts, but she hoped they found a way. “I know that the museums, especially in America, have enormous trouble being funded and it’s so important museums stay open,” she said. “But museums are also about ethics and morality.”

    A spokeswoman for the Victoria and Albert Museum in London, which has a Sackler Courtyard, said in an emailed statement on Wednesday that the museum was “not considering the removal of any signage related to our past or present donors.”

    “We’re proud to have been supported by the Sacklers,” Tristram Hunt, the museum’s director, told the BBC on July 10.

    Tate did not intend to rename the Sackler escalator at Tate Modern, it said in an emailed statement on Wednesday.

    A spokeswoman for the Jewish Museum in Berlin said in a telephone interview on Wednesday that the Louvre’s move did not change an earlier statement about its Sackler staircase.

    “We will not be changing the name because we feel that renaming would be an inappropriate attempt to disguise what happened,” that statement, issued in March, said. “It would also contradict the fact that we acted in good faith.”

    #Opioides #Sackler #Louvre #Philanthropie

  • 76 billion opioid pills : Newly released federal data unmasks the epidemic

    https://www.washingtonpost.com/investigations/76-billion-opioid-pills-newly-released-federal-data-unmasks-the-epidemic/2019/07/16/5f29fd62-a73e-11e9-86dd-d7f0e60391e9_story.html

    America’s largest drug companies saturated the country with 76 billion oxycodone and hydrocodone pain pills from 2006 through 2012 as the nation’s deadliest drug epidemic spun out of control, according to previously undisclosed company data released as part of the largest civil action in U.S. history.

    The information comes from a database maintained by the Drug Enforcement Administration that tracks the path of every single pain pill sold in the United States — from manufacturers and distributors to pharmacies in every town and city. The data provides an unprecedented look at the surge of legal pain pills that fueled the prescription opioid epidemic, which has resulted in nearly 100,000 deaths from 2006 through 2012.

    Just six companies distributed 75 percent of the pills during this period: McKesson Corp., Walgreens, Cardinal Health, AmerisourceBergen, CVS and Walmart, according to an analysis of the database by The Washington Post. Three companies manufactured 88 percent of the opioids: SpecGx, a subsidiary of Mallinckrodt; ­Actavis Pharma; and Par Pharmaceutical, a subsidiary of Endo Pharmaceuticals.

    The database reveals what each company knew about the number of pills it was shipping and dispensing and precisely when they were aware of those volumes, year by year, town by town. In case after case, the companies allowed the drugs to reach the streets of communities large and small, despite persistent red flags that those pills were being sold in apparent violation of federal law and diverted to the black market, according to the lawsuits.

    In statements emailed to The Post on Tuesday, the drug distributors stressed that the ARCOS data would not exist unless they had accurately reported shipments and questioned why the government had not done more to address the crisis.

    “For decades, DEA has had exclusive access to this data, which can identify the total volumes of controlled substances being ordered, pharmacy-by-pharmacy, across the country,” McKesson spokeswoman Kristin Chasen said.

    A DEA spokeswoman declined to comment Tuesday “due to ongoing litigation.”

    The pain pill epidemic began nearly three decades ago, shortly after Purdue Pharma introduced what it marketed as a less addictive form of opioid it called OxyContin. Purdue paid doctors and nonprofit groups advocating for patients in pain to help market the drug as a safe and effective way to treat pain.

    But the new drug was highly addictive. As more and more people were hooked, more and more companies entered the market, manufacturing, distributing and dispensing massive quantities of pain pills.

    Purdue ending up paying a $634 million fine to the Food and Drug Administration for claiming OxyContin was less addictive than other pain medications.

    Annual opioid sales nationwide rose from $6.1 billion in 2006 to $8.5 billion in 2012, according to industry data gathered by IQVIA, a health care information and consulting company.

    Individual drug company revenues ranged in single years at the epidemic’s peak from $403 million for opioids sold by Endo to $3.1 billion in OxyContin sales by Purdue Pharma, according to a 2018 lawsuit against multiple defendants by San Juan County in New Mexico.

    During the past two decades, Florida became ground zero for pill mills — pain management clinics that served as fronts for corrupt doctors and drug dealers. They became so brazen that some clinics set up storefronts along I-75 and I-95, advertising their products on billboards by interstate exit ramps. So many people traveled to Florida to stock up on oxycodone and hydrocodone, they were sometimes referred to as “prescription tourists.”

    In 2007, the DEA brought a case against McKesson. The DEA accused the company of shipping millions of doses of hydrocodone to Internet pharmacies after the agency had briefed the company about its obligations under the law to report suspicious orders.

    “By failing to report suspicious orders for controlled substances that it received from rogue Internet pharmacies, the McKesson Corporation fueled the explosive prescription drug abuse problem we have in this country,” the DEA’s administrator said at the time.

    In 2008, McKesson agreed to pay a $13.25 million fine to settle the case and pledged to more closely monitor suspicious orders from its customers.

    That same year, the DEA brought a case against Cardinal Health, accusing the nation’s ­second-largest drug distributor of shipping millions of doses of painkillers to online and retail pharmacies without notifying the DEA of signs that the drugs were being diverted to the black market.

    “The depth and penetration of the opioid epidemic becomes readily apparent from the data,” said Peter J. Mougey, a lawyer for the plaintiffs from Pensacola, Fla. “This disclosure will serve as a wake up call to every community in the country. America should brace itself for the harsh reality of the scope of the opioid epidemic. Transparency will lead to accountability .”

    #Opioides #Oxycondone #Vente_opiacés #USA #Big_Pharma

  • Facebook Is Censoring Harm Reduction Posts That Could Save Opioid Users’ Lives
    https://www.vice.com/en_us/article/qv75ap/facebook-is-censoring-harm-reduction-posts-that-could-save-opioid-users-lives

    As Facebook rolls out its campaign with the Partnership for Drug-Free Kids to “Stop Opioid Silence” and other initiatives to fight the overdose crisis, some stalwart advocates in the field are seeing unwelcome changes. In the past few months, accounts have been disabled, groups have disappeared, posts containing certain content—particularly related to fentanyl—have been removed, and one social media manager reports being banned for life from advertising on Facebook.

    In its efforts to stop opioid sales on the site, Facebook appears to be blocking people who warn users about poisonous batches of drugs or who supply materials used to test for fentanyls and other contaminants. Just as 1990s web security filters mistook breast cancer research centers for porn sites, today’s internet still seems to have trouble distinguishing between drug dealers and groups trying to reduce the death toll from the overdose crisis. VICE reviewed screenshots and emails to corroborate the claims made in this story.

    Facebook seems to be especially focused on fentanyl. Claire Zagorski, a wound care paramedic at the Austin Harm Reduction Coalition in Texas, said she informally surveyed other harm reduction groups about their experiences. About half a dozen reported problems with reduced distribution of posts or outright rejection—especially if they were trying to report a specific, local instance of fentanyl-tainted drugs. Two of the organizations affected were a harm reduction group called Shot in the Dark in Phoenix, Arizona, and Southside Harm Reduction Services in Minneapolis, Minnesota.

    “I think it’s important to remember that they’re not being like, ‘Hooray drugs!’" Zagorski said. "They’re saying, ‘Be warned that this contaminated supply could be lethal.’”

    Devin Reaves, executive director and co-founder of the Pennsylvania Harm Reduction Coalition, who hasn’t personally had posts blocked, said: “Facebook wants to address the opioid crisis, but when harm reductionists try to inform their communities about what’s dangerous, their posts are being blocked.”

    Why then is Facebook cracking down?

    When reached for comment, a Facebook spokesperson said the company is investigating these incidents. After VICE contacted Facebook, the company restored posts from Southside Harm Reduction and Shot in the Dark, as well as Louise Vincent’s ability to post her email address, which apparently triggered a spam filter unrelated to opioids.

    Facebook also told VICE that Marcom was blocked from posting ads due not to fentanyl test strips, but due to posts related to kratom, an herb used by some as a substitute for opioids. Facebook has decided that kratom is a “non-medical drug” and is removing posts and groups related to it—even though its use is considered to be a form of harm reduction.

    Marcom said he hadn’t posted any kratom-related ads since 2018 and added, “It’s extremely frustrating that they have chosen to ban a proven safe plant medicine, as Facebook used to be a space where tens of thousands went daily for help getting off of opiates and other pharmaceuticals.”

    #Facebook #Opioides #Liberté_expression #Régulation

  • Opioïdes : Nan Goldin vise le mécénat du Louvre - Libération
    https://www.liberation.fr/france/2019/07/01/opioides-nan-goldin-vise-le-mecenat-du-louvre_1737328

    La photographe a organisé lundi une action dans la cour du grand musée parisien, appelant sa direction à débaptiser une aile nommée en l’honneur d’une famille de mécènes détenant le laboratoire produisant l’Oxycontin, un puissant analgésique.

    Opioïdes : Nan Goldin vise le mécénat du Louvre

    Le Louvre n’imaginait sans doute pas voir un jour sa réputation ternie par la crise des opioïdes, ce scandale sanitaire majeur qui a déjà fait au moins 100 000 morts par overdose aux Etats-Unis. Le célèbre musée parisien doit pourtant faire face à une fronde inédite orchestrée par la photographe new-yorkaise Nan Goldin et le collectif PAIN (Pain Addiction Intervention Now), qui militent depuis deux ans pour alerter sur les dangers de l’Oxycontin. Ce puissant antidouleur, dérivé de l’opium, est commercialisé depuis 1996 par la société Purdue Pharma, elle-même détenue par la famille Sackler. Comme de nombreuses entreprises, le laboratoire américain est aussi un généreux mécène du monde de l’art, prêt à débourser de très grosses sommes pour voir son nom associé à des institutions culturelles de renom. Grâce à un don de 10 millions de francs au Louvre en 1996, la famille a ainsi obtenu que l’aile des antiquités orientales du Louvre soit nommée « aile Sackler », nom qu’elle porte toujours aujourd’hui. Douze salles consacrées à l’Iran ancien, au Levant et à l’Arabie ancienne, où trônent d’inestimables joyaux.

    Une association insupportable pour Nan Goldin, devenue la figure de proue de la lutte contre Sackler. Ancienne accro à l’Oxycontin dont elle est désormais sevrée, la photographe multiplie depuis 2017 les actions choc dans les musées financés par la famille américaine. Mais c’est la première fois qu’une action a lieu en France, face au musée le plus visité du monde.
    PUBLICITÉ
    inRead invented by Teads
    « Sackler on meurt, le Louvre couvre »

    Les touristes présents lundi devant la pyramide du Louvre ont d’abord cru à une performance artistique. Entièrement vêtue de noir, sa médaille de l’ordre des arts et des lettres attachée à la ceinture, Nan Goldin s’est avancée dans l’eau au milieu du bassin, face au bâtiment de verre. Puis des militants ont déployé derrière elle une large banderole orange avec ces mots en lettres noires : « Louvre, take down their name » (« Louvre, retirez leur nom »). Une trentaine d’activistes se sont ensuite massés autour de la photographe aux cris de « Shame on Sackler » et « Sackler on meurt, le Louvre couvre ». « Sackler est responsable de la mort de 200 personnes par jour aux Etats-Unis, lance Nan Goldin aux quelques journalistes présents. Le Louvre ne peut pas être complice de ce scandale. »

    Préparée en trois semaines dans le plus grand secret, l’action a été menée en collaboration avec l’association Aides. « On ne parle que des Etats-Unis mais d’autres pays commencent à être touchés par la crise des opioïdes, explique Fred Bladou, chargé de mission au sein de l’asso. Ce désastre sanitaire doit aussi nous interpeller sur la politique préventive que nous menons. Il démontre l’absurdité qu’il y a à criminaliser les usagers de drogue illicite alors qu’une des plus grosses crises sanitaires de l’histoire concerne une drogue licite. » En France, une centaine de médecins ont alerté fin juin dans les colonnes du JDD sur « le risque d’une crise sanitaire » alors que « 12 millions de Français utilisent des médicaments opiacés, sans être alertés sur leur potentiel addictif et sur les risques d’overdose ».
    Guggenheim et Tate Modern

    Accusés de commercialiser son produit phare en toute connaissance de cause, les Sackler sont aujourd’hui visés par plus de 1 600 actions en justice dans 35 Etats américains. En mars, ils ont dû verser 270 millions de dollars dans le cadre d’un accord à l’amiable passé avec l’Etat de l’Oklahoma. Sous la pression de PAIN, la polémique s’est étendue au mécénat culturel international. Ces derniers mois, plusieurs grands musées comme le Guggenheim et le Metropolitan Museum of Art à New York, ou la Tate Modern à Londres, ont annoncé publiquement qu’ils refuseraient à l’avenir toute donation de la famille Sackler. Un autre musée londonien, la National Portrait Gallery, a décliné en mars un don d’un million de livres (1,15 million d’euros). « Nous n’avons plus reçu aucune donation ni aucune demande de Sackler depuis 1996 », se défend-on au Louvre. Mais ce refus des dons ne suffit plus, pour Nan Goldin et les militants de PAIN. « Il faut que le Louvre soit le premier à débaptiser une aile, exigent-ils dans leur communiqué. Nous n’acceptons plus qu’une institution culturelle publique financée par l’Etat et les contribuables porte au pinacle une entreprise meurtrière. »

    Techniquement, rien n’empêche le musée parisien de retirer le nom des Sackler, le choix de baptiser certaines salles n’étant pas irrévocable, selon la charte interne. Mais la problématique du mécénat et des donateurs embarrassants va bien au-delà de ce cas. Elle est d’autant plus sensible qu’en vingt ans, le budget du Louvre a plus que doublé, alors même que la subvention de l’Etat est restée stable (environ 100 millions d’euros par an). Pour financer la différence et satisfaire les dix millions de visiteurs annuels, le musée n’a d’autre choix que de se tourner vers les acteurs privés, qui représentent entre 20 et 25 millions d’euros par an. Pour vérifier l’origine de ces fonds, le Louvre s’appuie aussi bien sur son réseau diplomatique dans les ambassades étrangères que sur Tracfin, le service antiblanchiment de Bercy. A l’époque, la donation des Sackler n’avait soulevé aucun problème. Vingt-trois ans et plusieurs dizaines de milliers de morts plus tard, c’est une tout autre affaire.
    Emmanuel Fansten

    #Opioides #Sackler #Louvre

  • Opioïdes : Nan Goldin vise le mécénat du Louvre
    https://www.liberation.fr/france/2019/07/01/opioides-nan-goldin-vise-le-mecenat-du-louvre_1737328

    La photographe a organisé lundi une action dans la cour du grand musée parisien, appelant sa direction à débaptiser une aile nommée en l’honneur d’une famille de mécènes détenant le laboratoire produisant l’Oxycontin, un puissant analgésique.

    Préparée en trois semaines dans le plus grand secret, l’action a été menée en collaboration avec l’association Aides. « On ne parle que des Etats-Unis mais d’autres pays commencent à être touchés par la crise des #opioïdes , explique Fred Bladou, chargé de mission au sein de l’asso. Ce désastre sanitaire doit aussi nous interpeller sur la politique préventive que nous menons. Il démontre l’absurdité qu’il y a à criminaliser les usagers de drogue illicite alors qu’une des plus grosses crises sanitaires de l’histoire concerne une drogue licite. » En France, une centaine de médecins ont alerté fin juin dans les colonnes du JDD sur « le risque d’une crise sanitaire » alors que « 12 millions de Français utilisent des médicaments opiacés, sans être alertés sur leur potentiel addictif et sur les risques d’overdose ».

    • Je présume que oui car deux personnes sont venus me voire le soir du vernissage de l’expo à la Hall Saint Pierre ou je présente un dessin sur ce sujet ( réalisé grâce aux nombreuses infos partagé ici par @hlc merci @hlc ). Donc deux hommes sont venu me voire discrètement, un m’a dit s’être « sorti de cette merde » et l’autre est venu me dire qu’il était encore en plein dedans. Je les ai rencontré à Paris, mais c’est possible que ca ne soit pas des résidents français (à un vernissage c’est pas les catégories ouvrières qui sont les plus représentées). J’ai souvenir d’une émission radio sur la question des opioïdes en France, probablement france culture. Le médecin qui y intervenait trouvait que c’etait une classe de médicaments sous prescrit en France car selon lui nous n’avons pas une culture contre la souffrance, et les medecins ne préscrivent pas facilement des anti-douleurs en comparaison aux anglo-saxons qui sont très généreux là dessus. Je pense que c’est sur seenthis, je reviens mettre le lien si je trouve.
      Il y a aussi un article à ce sujet dans le livre de @hlc https://seenthis.net/messages/790327

      Edit : j’ai pas trouvé mais j’ai cet article qui devrais répondre à ta question
      https://seenthis.net/messages/762674